Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease

Fig. 1

Annual rate of lung density change from baseline to 24 and 48 months in the RAPID trial [11]. At baseline (0 months), patients are randomly assigned to receive either A1Pl or placebo (placebo-controlled phase) and they are followed for 24 months. Then, patients in the placebo group switch to the investigational treatment for another 24 months (active treatment phase)

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172